Abbott Laboratories
ABT
$113.61
-$0.51-0.45%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 44.33B | 43.84B | 43.11B | 42.34B | 41.95B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 44.33B | 43.84B | 43.11B | 42.34B | 41.95B |
| Cost of Revenue | 19.30B | 19.26B | 18.89B | 18.64B | 18.64B |
| Gross Profit | 25.03B | 24.58B | 24.22B | 23.71B | 23.31B |
| SG&A Expenses | 12.86B | 12.56B | 12.42B | 12.27B | 12.19B |
| Depreciation & Amortization | 1.68B | 1.73B | 1.78B | 1.83B | 1.88B |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 36.75B | 36.47B | 35.95B | 35.58B | 35.54B |
| Operating Income | 7.57B | 7.37B | 7.16B | 6.77B | 6.41B |
| Income Before Tax | 8.47B | 8.14B | 7.90B | 7.36B | 7.01B |
| Income Tax Expenses | 1.94B | -5.84B | -6.08B | -6.15B | -6.39B |
| Earnings from Continuing Operations | 6.52K | 13.98K | 13.98K | 13.50K | 13.40K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 6.52B | 13.98B | 13.98B | 13.50B | 13.40B |
| EBIT | 7.57B | 7.37B | 7.16B | 6.77B | 6.41B |
| EBITDA | 10.69B | 10.50B | 10.30B | 9.94B | 9.63B |
| EPS Basic | 3.73 | 8.01 | 8.01 | 7.74 | 7.68 |
| Normalized Basic EPS | 3.08 | 2.98 | 2.89 | 2.75 | 2.61 |
| EPS Diluted | 3.71 | 7.97 | 7.97 | 7.70 | 7.64 |
| Normalized Diluted EPS | 3.07 | 2.97 | 2.88 | 2.74 | 2.60 |
| Average Basic Shares Outstanding | 6.97B | 6.97B | 6.97B | 6.97B | 6.97B |
| Average Diluted Shares Outstanding | 6.99B | 6.99B | 6.99B | 6.99B | 6.99B |
| Dividend Per Share | 2.40 | 2.36 | 2.32 | 2.28 | 2.24 |
| Payout Ratio | 63.09% | 28.93% | 28.42% | 28.92% | 28.62% |